15.40
+1.47(+10.55%)
Currency In USD
| Previous Close | 13.93 |
| Open | 13.68 |
| Day High | 15.82 |
| Day Low | 13.4 |
| 52-Week High | 98 |
| 52-Week Low | 11.13 |
| Volume | 52,564 |
| Average Volume | 97,334 |
| Market Cap | 144.59M |
| PE | -1.64 |
| EPS | -9.37 |
| Moving Average 50 Days | 18.77 |
| Moving Average 200 Days | 37.81 |
| Change | 1.47 |
If you invested $1000 in Korro Bio, Inc. (KRRO) since IPO date, it would be worth $22.48 as of May 09, 2025 at a share price of $15.4. Whereas If you bought $1000 worth of Korro Bio, Inc. (KRRO) shares 5 years ago, it would be worth $16.87 as of May 09, 2025 at a share price of $15.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
GlobeNewswire Inc.
Apr 01, 2025 11:30 AM GMT
Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting OfficerCAMBRIDGE,
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
GlobeNewswire Inc.
Mar 14, 2025 12:00 PM GMT
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent d
Korro to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 26, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent di